Abciximab administration and outcome after intracoronary stent implantation

David Hasdai, Charanjit Rihal, Malcolm R. Bell, Peter B. Berger, Diane E. Grill, Kirk N. Garratt, David Holmes

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Although adjunctive abciximab therapy improves outcome after angioplasty or atherectomy, there are few data demonstrating its benefit for intracoronary stent implantation. We characterized patients receiving abciximab for stent placement in our practice and determined the impact of abciximab on outcome. Abciximab was introduced to our practice in April 1995 for percutaneous revascularization. Demographic, clinical, and angiographic variables that were independently associated with the use of abciximab for stent placement through 1996 (abciximab era) were examined. We then examined among all patients receiving stents from 1992 through 1996 (preabciximab and abciximab eras) whether the use of abciximab was independently associated with improved outcome (death, nonfatal Q-wave myocardial infarction, coronary bypass surgery, or target vessel percutaneous revascularization) in the hospital and at 30 days. The 30-day event rate was 7% for those who did or did not receive abciximab. The following characteristics were independently associated with the use of abciximab for stent placement in the abciximab era: thrombus before stent placement (chi-square 50.5), ≥2 stents implanted (chi-square 10.8), stent in venous graft (chi-square 7.4), calcific lesion (chi-square 5.8), and hypertension (chi-square 5.5). Among all patients receiving stents in the preabciximab and abciximab eras (n = 1,859), the presence of these characteristics was independently associated with worse outcome. Abciximab, however, did not improve outcome in the hospital (odds ratio [95% confidence interval] = 0.96 [0.58 to 1.58]) or at 30 days (0.87 [0.53 to 1.41]), even after adjusting for these characteristics. Abciximab for stent placement was used in high-risk patients in our practice but was not associated with improved outcome.

Original languageEnglish (US)
Pages (from-to)705-709
Number of pages5
JournalAmerican Journal of Cardiology
Volume82
Issue number6 A
StatePublished - 1998

Fingerprint

Stents
abciximab
Atherectomy
Angioplasty
Thrombosis
Odds Ratio
Myocardial Infarction
Demography
Confidence Intervals
Hypertension
Transplants

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Hasdai, D., Rihal, C., Bell, M. R., Berger, P. B., Grill, D. E., Garratt, K. N., & Holmes, D. (1998). Abciximab administration and outcome after intracoronary stent implantation. American Journal of Cardiology, 82(6 A), 705-709.

Abciximab administration and outcome after intracoronary stent implantation. / Hasdai, David; Rihal, Charanjit; Bell, Malcolm R.; Berger, Peter B.; Grill, Diane E.; Garratt, Kirk N.; Holmes, David.

In: American Journal of Cardiology, Vol. 82, No. 6 A, 1998, p. 705-709.

Research output: Contribution to journalArticle

Hasdai, D, Rihal, C, Bell, MR, Berger, PB, Grill, DE, Garratt, KN & Holmes, D 1998, 'Abciximab administration and outcome after intracoronary stent implantation', American Journal of Cardiology, vol. 82, no. 6 A, pp. 705-709.
Hasdai D, Rihal C, Bell MR, Berger PB, Grill DE, Garratt KN et al. Abciximab administration and outcome after intracoronary stent implantation. American Journal of Cardiology. 1998;82(6 A):705-709.
Hasdai, David ; Rihal, Charanjit ; Bell, Malcolm R. ; Berger, Peter B. ; Grill, Diane E. ; Garratt, Kirk N. ; Holmes, David. / Abciximab administration and outcome after intracoronary stent implantation. In: American Journal of Cardiology. 1998 ; Vol. 82, No. 6 A. pp. 705-709.
@article{bbdbba92235248c7ab8e16cd46e18001,
title = "Abciximab administration and outcome after intracoronary stent implantation",
abstract = "Although adjunctive abciximab therapy improves outcome after angioplasty or atherectomy, there are few data demonstrating its benefit for intracoronary stent implantation. We characterized patients receiving abciximab for stent placement in our practice and determined the impact of abciximab on outcome. Abciximab was introduced to our practice in April 1995 for percutaneous revascularization. Demographic, clinical, and angiographic variables that were independently associated with the use of abciximab for stent placement through 1996 (abciximab era) were examined. We then examined among all patients receiving stents from 1992 through 1996 (preabciximab and abciximab eras) whether the use of abciximab was independently associated with improved outcome (death, nonfatal Q-wave myocardial infarction, coronary bypass surgery, or target vessel percutaneous revascularization) in the hospital and at 30 days. The 30-day event rate was 7{\%} for those who did or did not receive abciximab. The following characteristics were independently associated with the use of abciximab for stent placement in the abciximab era: thrombus before stent placement (chi-square 50.5), ≥2 stents implanted (chi-square 10.8), stent in venous graft (chi-square 7.4), calcific lesion (chi-square 5.8), and hypertension (chi-square 5.5). Among all patients receiving stents in the preabciximab and abciximab eras (n = 1,859), the presence of these characteristics was independently associated with worse outcome. Abciximab, however, did not improve outcome in the hospital (odds ratio [95{\%} confidence interval] = 0.96 [0.58 to 1.58]) or at 30 days (0.87 [0.53 to 1.41]), even after adjusting for these characteristics. Abciximab for stent placement was used in high-risk patients in our practice but was not associated with improved outcome.",
author = "David Hasdai and Charanjit Rihal and Bell, {Malcolm R.} and Berger, {Peter B.} and Grill, {Diane E.} and Garratt, {Kirk N.} and David Holmes",
year = "1998",
language = "English (US)",
volume = "82",
pages = "705--709",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "6 A",

}

TY - JOUR

T1 - Abciximab administration and outcome after intracoronary stent implantation

AU - Hasdai, David

AU - Rihal, Charanjit

AU - Bell, Malcolm R.

AU - Berger, Peter B.

AU - Grill, Diane E.

AU - Garratt, Kirk N.

AU - Holmes, David

PY - 1998

Y1 - 1998

N2 - Although adjunctive abciximab therapy improves outcome after angioplasty or atherectomy, there are few data demonstrating its benefit for intracoronary stent implantation. We characterized patients receiving abciximab for stent placement in our practice and determined the impact of abciximab on outcome. Abciximab was introduced to our practice in April 1995 for percutaneous revascularization. Demographic, clinical, and angiographic variables that were independently associated with the use of abciximab for stent placement through 1996 (abciximab era) were examined. We then examined among all patients receiving stents from 1992 through 1996 (preabciximab and abciximab eras) whether the use of abciximab was independently associated with improved outcome (death, nonfatal Q-wave myocardial infarction, coronary bypass surgery, or target vessel percutaneous revascularization) in the hospital and at 30 days. The 30-day event rate was 7% for those who did or did not receive abciximab. The following characteristics were independently associated with the use of abciximab for stent placement in the abciximab era: thrombus before stent placement (chi-square 50.5), ≥2 stents implanted (chi-square 10.8), stent in venous graft (chi-square 7.4), calcific lesion (chi-square 5.8), and hypertension (chi-square 5.5). Among all patients receiving stents in the preabciximab and abciximab eras (n = 1,859), the presence of these characteristics was independently associated with worse outcome. Abciximab, however, did not improve outcome in the hospital (odds ratio [95% confidence interval] = 0.96 [0.58 to 1.58]) or at 30 days (0.87 [0.53 to 1.41]), even after adjusting for these characteristics. Abciximab for stent placement was used in high-risk patients in our practice but was not associated with improved outcome.

AB - Although adjunctive abciximab therapy improves outcome after angioplasty or atherectomy, there are few data demonstrating its benefit for intracoronary stent implantation. We characterized patients receiving abciximab for stent placement in our practice and determined the impact of abciximab on outcome. Abciximab was introduced to our practice in April 1995 for percutaneous revascularization. Demographic, clinical, and angiographic variables that were independently associated with the use of abciximab for stent placement through 1996 (abciximab era) were examined. We then examined among all patients receiving stents from 1992 through 1996 (preabciximab and abciximab eras) whether the use of abciximab was independently associated with improved outcome (death, nonfatal Q-wave myocardial infarction, coronary bypass surgery, or target vessel percutaneous revascularization) in the hospital and at 30 days. The 30-day event rate was 7% for those who did or did not receive abciximab. The following characteristics were independently associated with the use of abciximab for stent placement in the abciximab era: thrombus before stent placement (chi-square 50.5), ≥2 stents implanted (chi-square 10.8), stent in venous graft (chi-square 7.4), calcific lesion (chi-square 5.8), and hypertension (chi-square 5.5). Among all patients receiving stents in the preabciximab and abciximab eras (n = 1,859), the presence of these characteristics was independently associated with worse outcome. Abciximab, however, did not improve outcome in the hospital (odds ratio [95% confidence interval] = 0.96 [0.58 to 1.58]) or at 30 days (0.87 [0.53 to 1.41]), even after adjusting for these characteristics. Abciximab for stent placement was used in high-risk patients in our practice but was not associated with improved outcome.

UR - http://www.scopus.com/inward/record.url?scp=0032530523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032530523&partnerID=8YFLogxK

M3 - Article

VL - 82

SP - 705

EP - 709

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 6 A

ER -